Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VDR | P11473 | 9/20 | 0.49 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | ESRRB | O95718 | 1/20 | 0.34 |
| ▸ | ESRRG | P62508 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13709354 | 0.83 | VDR (0.41) | VDRS1PR1HDAC3HDAC6EPHX2 | |
| SCHEMBL13709353 | 0.83 | VDR (0.42) | VDRHDAC3HDAC6EPHX2NR1H4 | |
| SCHEMBL13709348 | 0.82 | VDR (0.39) | VDRHDAC3HDAC6EPHX2NR1H4 | |
| SCHEMBL13709269 | 0.81 | VDR (0.37) | VDRS1PR1HDAC3HDAC6EPHX2 | |
| SCHEMBL13709307 | 0.80 | VDR (0.37) | VDRS1PR1HDAC3HDAC6CA1 | |
| SCHEMBL13709359 | 0.80 | VDR (0.35) | VDRHDAC3HDAC6EPHX2 | |
| SCHEMBL13709347 | 0.80 | HDAC6 (0.59) | VDRHDAC3HDAC6 | |
| SCHEMBL13709274 | 0.79 | VDR (0.39) | VDRS1PR1HDAC3HDAC6EPHX2 | |
| SCHEMBL13709311 | 0.78 | VDR (0.39) | VDRS1PR1HDAC3HDAC6EPHX2 | |
| SCHEMBL5153709 | 0.77 | NPSR1 (0.49) | VDRHDAC3HDAC6NR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7595345-B2 | Vitamin D receptor modulators | ELI LILLY AND COMPANY (US) | 2009-09-29 | — | — | US | disclosed |
| US-7595345-B2 | Vitamin D receptor modulators | ELI LILLY AND COMPANY (US) | 2009-09-29 | — | — | US | disclosed |
| US-20080200552-A1 | Vitamin D Receptor Modulators | ELI LILLY AND COMPANY (IN) | 2008-08-21 | — | — | US | disclosed |
| US-20080200552-A1 | Vitamin D Receptor Modulators | ELI LILLY AND COMPANY (IN) | 2008-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200552-A1 | Vitamin D Receptor Modulators | VDR, CYP2R1, CYP24A1 | VDR 1/4885S1PR1 174/4885HDAC3 1756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.